These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 12453332)
1. Capecitabine (Xeloda): from the laboratory to the patient's home. Pentheroudakis G; Twelves C Clin Colorectal Cancer; 2002 May; 2(1):16-23. PubMed ID: 12453332 [TBL] [Abstract][Full Text] [Related]
2. The rational development of capecitabine from the laboratory to the clinic. Pentheroudakis G; Twelves C Anticancer Res; 2002; 22(6B):3589-96. PubMed ID: 12552961 [TBL] [Abstract][Full Text] [Related]
3. Capecitabine: a review. Walko CM; Lindley C Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604 [TBL] [Abstract][Full Text] [Related]
4. Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. Twelves C; Boyer M; Findlay M; Cassidy J; Weitzel C; Barker C; Osterwalder B; Jamieson C; Hieke K; Eur J Cancer; 2001 Mar; 37(5):597-604. PubMed ID: 11290435 [TBL] [Abstract][Full Text] [Related]
5. [Mechanism and possible biochemical modulation of capecitabine (Xeloda), a newly generated oral fluoropyrimidine]. Saeki T; Takashima S Gan To Kagaku Ryoho; 1999 Mar; 26(4):447-55. PubMed ID: 10097741 [TBL] [Abstract][Full Text] [Related]
6. Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) trial: overview of efficacy, safety, and cost-effectiveness. Twelves CJ Clin Colorectal Cancer; 2006 Nov; 6(4):278-87. PubMed ID: 17241512 [TBL] [Abstract][Full Text] [Related]
7. A Phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumors. Cassidy J; Dirix L; Bissett D; Reigner B; Griffin T; Allman D; Osterwalder B; Van Oosterom AT Clin Cancer Res; 1998 Nov; 4(11):2755-61. PubMed ID: 9829739 [TBL] [Abstract][Full Text] [Related]
8. Capecitabine, a new oral fluoropyrimidine for the treatment of colorectal cancer. Di Costanzo F; Sdrobolini A; Gasperoni S Crit Rev Oncol Hematol; 2000 Aug; 35(2):101-8. PubMed ID: 10936467 [TBL] [Abstract][Full Text] [Related]
9. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Schüller J; Cassidy J; Dumont E; Roos B; Durston S; Banken L; Utoh M; Mori K; Weidekamm E; Reigner B Cancer Chemother Pharmacol; 2000; 45(4):291-7. PubMed ID: 10755317 [TBL] [Abstract][Full Text] [Related]
10. Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients. Poole C; Gardiner J; Twelves C; Johnston P; Harper P; Cassidy J; Monkhouse J; Banken L; Weidekamm E; Reigner B Cancer Chemother Pharmacol; 2002 Mar; 49(3):225-34. PubMed ID: 11935215 [TBL] [Abstract][Full Text] [Related]
11. [Capecitabine]. Yamaguchi K; Shimamura T; Tada M Gan To Kagaku Ryoho; 2006 Jul; 33(7):891-5. PubMed ID: 16835474 [TBL] [Abstract][Full Text] [Related]
12. Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer. Rossi D; Alessandroni P; Catalano V; Giordani P; Fedeli SL; Fedeli A; Baldelli AM; Casadei V; Ceccolini M; Catalano G Clin Breast Cancer; 2007 Dec; 7(11):857-60. PubMed ID: 18269775 [TBL] [Abstract][Full Text] [Related]
13. Potential of Xeloda in colorectal cancer and other solid tumors. Cassidy J Oncology; 1999 Jul; 57 Suppl 1():27-32. PubMed ID: 10436414 [TBL] [Abstract][Full Text] [Related]
15. Development of and clinical experience with capecitabine (Xeloda) in the treatment of solid tumours. Sternberg CN; Reichardt P; Holland M Eur J Oncol Nurs; 2004; 8 Suppl 1():S4-15. PubMed ID: 15341878 [TBL] [Abstract][Full Text] [Related]
16. Pharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancer. Aprile G; Mazzer M; Moroso S; Puglisi F Anticancer Drugs; 2009 Apr; 20(4):217-29. PubMed ID: 19247178 [TBL] [Abstract][Full Text] [Related]
17. [Pharmacological and clinical properties of Xeloda (Capecitabine), a new oral active derivative of fluoropyrimidine]. Nishida M Nihon Yakurigaku Zasshi; 2003 Dec; 122(6):549-53. PubMed ID: 14639009 [TBL] [Abstract][Full Text] [Related]
18. The evolution of fluoropyrimidine therapy: from intravenous to oral. Hoff PM; Cassidy J; Schmoll HJ Oncologist; 2001; 6 Suppl 4():3-11. PubMed ID: 11585968 [TBL] [Abstract][Full Text] [Related]
19. Evolution of capecitabine dosing in colorectal cancer. Sun W Clin Colorectal Cancer; 2010 Jan; 9(1):31-9. PubMed ID: 20100686 [TBL] [Abstract][Full Text] [Related]
20. Rational development of capecitabine. Venturini M Eur J Cancer; 2002 Feb; 38 Suppl 2():3-9. PubMed ID: 11841929 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]